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#2014-1Over the past three decades, medical methods of abortion
have been developed throughout the world and are now a
standard method of providing abortion care in the United
States. Medical abortion, which involves the use of
medications rather than a surgical procedure to induce an
abortion, is an option for women who wish to terminate a
first-trimester pregnancy. Although the method is most
commonly used up to 63 days of gestation (calculated from
the first day of the last menstrual period), the treatment also
is effective after 63 days of gestation. The Centers for
Disease Control and Prevention estimates that 64% of
abortions are performed before 63 days of gestation [1].
Medical abortions currently comprise 16.5% of all abortions
in the United States and 25.2% of all abortions at or before
9 weeks of gestation [1]. Mifepristone, combined with
misoprostol, is the most commonly used medical abortion
regimen in the United States and Western Europe; however,
in parts of the world, mifepristone remains unavailable. This
document presents evidence of the effectiveness, benefits,☆ Published concurrently in the March 2014 issue of Obstetrics & Gynecology.
☆☆ CopyrightMarch 2014 by theAmerican College ofObstetricians andGynecolo
in a retrieval system, posted on the Internet, or transmitted, in any form or by anymean
written permission from the publisher.
☆☆☆ Requests for authorization to make photocopies should be directed to Cop
750-8400.
☆☆☆☆ ISSN 1099-3630
★ The American College of Obstetricians and Gynecologists, 409 12th Street, S
★★ Medical management of first-trimester abortion. Practice Bulletin No. 14
2014;123:676−692.
★★★ Committee on Practice Bulletins — Gynecology and the Society of Family
Bulletins — Gynecology and the Society of Family Planning with the assistance of
designed to aid practitioners in making decisions about appropriate obstetric and gyne
course of treatment or procedure. Variations in practicemay bewarranted based on the n
or type of practice.
0010-7824/ – see front matter © 2014 Elsevier Inc.
http://dx.doi.org/10.1016/j.contraception.2014.01.016
Open access under CC BY-NC-NDand risks of first-trimester medical abortion and provides a
framework for counseling women who are considering
medical abortion.1. Background
1.1. Medications currently used for medical abortion
1.1.1. Mifepristone
Mifepristone, a derivative of norethindrone, binds to the
progesterone receptor with an affinity greater than proges-
terone itself but does not activate the receptor, thereby acting
as an antiprogestin [2]. Its known actions on a uterus in
pregnant women include decidual necrosis, cervical soften-
ing, and increased uterine contractility and prostaglandin
sensitivity [3,4]. Human studies have suggested that uterine
contractility does not increase until 24–36 h after mifepris-
tone administration [3]. At this point, the sensitivity of the
myometrium to the stimulatory effects of exogenousgists. All rights reserved. No part of this publicationmay be reproduced, stored
s, electronic, mechanical, photocopying, recording, or otherwise, without prior
yright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978)
W, PO Box 96920, Washington, DC 20090-6920
3. American College of Obstetricians and Gynecologists. Obstet Gynecol
Planning. This Practice Bulletin was developed by the Committee on Practice
Mitchell D. Creinin, M.D., and Daniel A. Grossman, M.D. The information is
cologic care. These guidelines should not be construed as dictating an exclusive
eeds of the individual patient, resources, and limitations unique to the institution
 license.
149Society of Family Planning / Contraception 89 (2014) 148–161prostaglandins increases fivefold [3]. However, more recent
studies have shown high efficacy when vaginal misoprostol
is administered less than 15 min after mifepristone [5]. The
effectiveness of such a regimen cannot be attributed to the
actions of the misoprostol because misoprostol alone has a
much lower efficacy than mifepristone. Accordingly, these
studies suggest that some or all of these actions occur sooner
than previously believed or that the effects of mifepristone
that are important and necessary for its abortifacient activity
remain incompletely understood.
As a progesterone receptor antagonist, mifepristone also
has several other potential medical applications, including
emergency contraception; cervical ripening and labor
induction; and treatment of symptomatic uterine leiomyo-
mas, endometriosis, Cushing syndrome, breast cancer, early
pregnancy loss, and glaucoma [6,7].1.1.2. Misoprostol
Misoprostol is an inexpensive prostaglandin E1 analogue in
a tablet form that is stable at room temperature. It is approved
by the US Food and Drug Administration (FDA) for oral
administration to prevent gastric ulcers in individuals who take
antiinflammatory drugs on a long-term basis, and it is included
in the FDA-approved labeling of mifepristone for use in
abortion. It is used off-label in other regimens for abortion,
labor induction, treatment of early pregnancy loss, prevention
and treatment of postpartum hemorrhage, and cervical priming
before uterine procedures, such as hysteroscopy [8]. Pharma-
cokinetic evaluations of misoprostol absorption when admin-
istered by various routes have been performed [9–13]. Routes
that result in a longer duration of action (i.e., buccal and
vaginal) also appear to result in greater efficacy comparedwith
oral administration. Similarly, those routes with rapid and
significant absorption (i.e., sublingual) also have high efficacy,
but the greatermaximum concentration results inmore adverse
effects. Misoprostol-only medical abortion regimens are
significantly less effective than those that use a combination
of mifepristone and misoprostol [14,15].1.1.3. Other agents
Methotrexate in combination with misoprostol was
adopted in the United States and Canada as an alternative
to mifepristone regimens before mifepristone was avail-
able [16,17]. However, methotrexate rarely is used
anymore in the United States for medical abortion because
of the greater availability and efficacy of mifepristone
regimens. Methotrexate blocks dihydrofolate reductase, an
enzyme involved in producing thymidine during DNA
synthesis. Methotrexate exerts its action primarily on
the cytotrophoblast rather than the developing embryo,
which inhibits syncytialization of the cytotrophoblast [18].
Thus, methotrexate stops the process of implantation
rather than weakening the implantation site directly. In
contrast, the antiprogestin mifepristone has no direct effect
on the trophoblast.Tamoxifen has been used in some studies of early
abortion in combination with misoprostol. However, ran-
domized trials have demonstrated no benefit of using
tamoxifen–misoprostol over methotrexate–misoprostol or
misoprostol alone regimens [19,20].
Two small studies from China suggest that multiple daily
administrations of letrozole followed by misoprostol, 800 mcg
vaginally, may be another effective option formedical abortion,
but more research is needed regarding this regimen [21,22].2. Mifepristone regimens
2.1. Regimen approved by the US Food and
Drug Administration
The FDA-approved regimen, as detailed in the mifepris-
tone package labeling, is based on the original regimen
registered in France 25 years ago. This regimen includes
mifepristone, 600 mg orally, followed approximately 48 h
later by a prostaglandin analogue, usually misoprostol 400
mcg orally. The FDA-approved regimen includes this
treatment with a follow-up visit approximately 14 days
after mifepristone administration [23]. If clinical history
indicates that the woman had a confirmed abortion, a pelvic
examination is performed to confirm uterine involution. If
clinical history and physical examination do not confirm
expulsion, ultrasonography is performed. Suction aspiration
at the follow-up evaluation is not specified as necessary
unless the pregnancy is ongoing [23].
The efficacy of the FDA-approved regimen is approxi-
mately 92% in women with gestations up to 49 days [24,25].
Complete abortion rates are higher with earlier gestations;
approximately 96–98% in gestations of up to 42 days, 91–
95% in gestations from 43 days to 49 days, and less than 85%
in gestations beyond 49 days [24,26,27]. When abortion does
not occur within 3–4 h after oral misoprostol administration,
use of an additional dose does not improve efficacy [26,28].3. Evidence-based regimens
Additional “evidence-based” regimens have been devel-
oped to improve medical abortion in terms of expense,
safety, speed, and adverse effects. Regimens that use low
doses of mifepristone (200 mg) have similar efficacy and
lower costs compared with those that use mifepristone at 600
mg [29]. Based on efficacy and the adverse effect profile,
evidence-based protocols for medical abortion are superior
to the FDA-approved regimen. Vaginal, buccal and
sublingual routes of misoprostol administration increase
efficacy, decrease continuing pregnancy rates and increase
the gestational age range for use as compared with the FDA-
approved regimen [30]. By changing the route of misopros-
tol administration, the timing between mifepristone and
misoprostol dosing can be varied to allow women more
flexibility to accommodate personal situations, such as work
150 Society of Family Planning / Contraception 89 (2014) 148–161and childcare. Regimens that use vaginal misoprostol can be
provided simultaneously with mifepristone to terminate
gestations of up to 63 days [5]. A 6–8-h interval between
mifepristone administration and vaginal misoprostol admin-
istration is as effective as a 24-h interval and results in
significantly fewer adverse effects [31]. Buccal and
sublingual misoprostol can be administered as early as 24
h after mifepristone administration [32,33]. Women can
safely and effectively self-administer misoprostol at home as
part of a medical abortion regimen [32,34,35].4. Counseling patients
4.1. Medical abortion vs. surgical abortion
Counseling must first emphasize early pregnancy options
to ensure that a woman is certain about her decision to have
an abortion. If she is uncertain, then the decision about
abortion technique must be delayed until she has reached a
firm decision, even if the delay means that she will be unable
to choose a medical option.
Only when a woman has considered her options and
decided to have an abortion does the discussion about the
different methods become an issue. Most women who seek
early abortion will be eligible for medical and surgical
methods. The general advantages and disadvantages of each
approach should be explained early in the counseling process
(Box 1) [36–38]. Even for women who think they are unsureBox 1
Features of medical and surgical abortion
Medical abortion
• Usually avoids invasive procedure
• Usually avoids anesthesia
• Days to weeks to complete
• Available during early pregnancy
• High success rate (approximately 95%)
• Bleeding commonly not perceived as light
• Requires follow-up to ensure completion
of abortion
• Patient participation throughout a multiple-step
process
Surgical abortion
• Involves invasive procedure
• Allows use of sedation if desired
• Complete in a predictable period of time
• Available during early pregnancy
• High success rate (99%)
• Bleeding commonly perceived as light
• Does not require follow-up in most cases
• Patient participation in a single-step processabout the method, most will have some preference after
counseling [37]. Studies that have compared abortion
method preferences have included groups of patients who
choose their method and those who are randomized to their
method. The applicability of these studies to current US
medical abortion practice is limited given that no studies
included the mifepristone−misoprostol regimen, and in two
studies, surgical abortion was performed only under general
anesthesia. Generally, women are satisfied with the method
they choose but, when randomized, prefer surgical abortion
to medical abortion [36–38].
Most women choose medical abortion because of a desire
to avoid surgery, a perception that medical abortion is safer
than surgical abortion, and a belief that medical abortion is
more natural and private than a surgical procedure [39].
Compared with surgical abortion, medical abortion takes
longer to complete, requires more active patient participa-
tion, and is associated with higher reported rates of bleeding
and cramping. With medical abortion, expulsion of the
products of conception most likely will occur at home, but a
few women will still require surgical evacuation to complete
the abortion. An early surgical abortion takes place most
commonly in one visit and involves less waiting and less
doubt about when the abortion occurs compared with
medical abortion. In addition, women who undergo surgical
abortion will not see any products of conception or blood
clots during the procedure.5. Adverse effects
Bleeding and cramping will be experienced by most
women undergoingmedical abortion and are necessary for the
process to occur. Adverse effects commonly associated with
mifepristone use include nausea, vomiting, diarrhea, head-
ache, dizziness, and thermoregulatory effects ([5,31,32,40–
42]; Table 1). The incidence of each adverse effect is based on
the regimen used (especially the prostaglandin analogue), the
dose and route of administration of the prostaglandin analogue
and the gestational age. Gastrointestinal adverse effects are
less common when misoprostol is administered vaginally as
compared with regimens that use oral, buccal, or sublingual
misoprostol [29,43]. Buccal and sublingual administration
cause similar adverse effects, with the sublingual route
associated with a higher rate of chills [44].
Counseling should emphasize that the woman is likely to
have bleeding that is much heavier than menses (and
potentially with severe cramping) and is best described to
patients as comparable with a miscarriage. The woman
should understand how much bleeding is considered too
much. An easy reference for the patient to use is the soaking
of two maxi pads per hour for 2 consecutive hours [45].
Patients should be advised to call their health care providers
if they experience this level of bleeding. The need for
emergency care is based on how the patient is feeling, her
baseline hemoglobin (Hb) or hematocrit level, whether the
Table 1
Adverse effects in selected North American trials of medical abortion regimens
Trial Incidence of adverse effects (%)
Nausea Vomiting Diarrhea Headache Dizziness Thermoregulatory effects*
Mifepristone Misoprostol Mifepristone Misoprostol Mifepristone Misoprostol Mifepristone Misoprostol Mifepristone Misoprostol Mifepristone Misoprostol
Schaff (1997)† 36 36 14 14 8 22 18 19 22 37 20 37
Schaff (1999)‡ 45 43 13 26 11 23 14 13 15 28 14 32
Wiebe (2002)§ 45 39 13 15 5 16 19 29 N/R N/R N/R 23
Creinin (2004)|| 20
39
44
52
5
14
23
30
1
7
27
25
10
20
37
37
12
20
35
37
9
19
56
53
Creinin (2007)¶ N/R 58 N/R 31 N/R 35 N/R 40 N/R 39 N/R 69
29 51 9 31 5 26 18 36 9 37 15 56
Winikoff (2008)# N/R 64 N/R 40 N/R 35 N/R 31 N/R 30 N/R 33
N/R 66 N/R 40 N/R 34 N/R 34 N/R 32 N/R 41
Abbreviation: N/R, not reported.
⁎ Fever, warmth, hot flushes or chills.
† Mifepristone, 600 mg, followed by misoprostol, 800 mcg vaginally, 36–48 h later. (Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for
abortion. J Fam Pract 1997;44:353–60.)
‡ Mifepristone, 200 mg, followed by misoprostol, 800 mcg vaginally, 48 h later. (Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal
misoprostol for abortion. Contraception 1999;59:1–6.)
§ Mifepristone, 600 mg, followed by misoprostol, 400 mcg orally, 36–48 h later. (Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed
by misoprostol. Obstet Gynecol 2002;99:813–9.)
|| Mifepristone, 200 mg, followed by misoprostol, 800 mcg vaginally, 6–8 h later (first row) or 24 h later (second row). (Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized
comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 2004;103:851–9.)
¶ Mifepristone, 200 mg, followed by misoprostol, 800 mcg vaginally, 0–15 minutes later (first row) or 24 hours later (second row). (Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn L.
Mifepristone and misoprostol administered simultaneously compared with 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol 2007;109:885–94.)
# Mifepristone, 200 mg, followed by misoprostol, 800 mcg orally (first row) or buccally (second row), 24–36 h later. (Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg A, Gonzales J, et al. Two
distinct oral routes of misoprostol in mifepristone medical abortion. A randomized controlled trial. Obstet Gynecol 2008;112:1303–10.)
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emergency facility. Overall, large series demonstrate that
less than 1% of women will need emergency curettage
because of excessive bleeding [26,46,47,41]. Moreover, the
risk of clinically significant bleeding and transfusion may be
lower in women who undergo medical abortion of gestations
up to 49 days compared with those who undergo medical
abortion of gestations of more than 49 days [24]; this risk
will vary based on the regimen used.
Pain management is an important consideration. The
woman should be sent home with appropriate instructions
for analgesia with over-the-counter medications and can be
provided with prescriptions for oral narcotics to use when
needed. Nonsteroidal antiinflammatory drugs, such as
ibuprofen, are not contraindicated in women who undergo
a medical abortion and are appropriate first-line agents for
pain management. One randomized trial found that
ibuprofen taken when needed was more effective than
acetaminophen to reduce pain associated with medical
abortion [48]. Nonsteroidal antiinflammatory drugs inhibit
the synthesis of new prostaglandins, but they do not block
the action of prostaglandin receptors and should not inhibit
the action of a prostaglandin used for medical abortion. In a
retrospective analysis of nonsteroidal antiinflammatory
drugs and complete abortion, in 416 women who received
misoprostol after methotrexate for medical abortion of
gestations up to 56 days, the use of ibuprofen did not
interfere with the action of misoprostol to induce uterine
contractions and expulsion of the products of conception
[49]. One randomized trial found that multiple doses of
ibuprofen given prophylactically at the time of misoprostol
administration did not significantly reduce pain associated
with medical abortion compared with ibuprofen taken when
needed [50].6. Need for surgical evacuation
The overall rate of surgical evacuation with medical
abortion varies greatly based on the regimen used, the
gestational age of the pregnancy, and many other factors. In
most studies of medical abortion of gestations up to 63 days
with mifepristone 200 mg followed by misoprostol, less than
5% of patients undergo surgical evacuation [51].
To determine whether a surgical evacuation is needed, it
is important to distinguish incomplete abortion from the
normal course of medical abortion. When an ultrasound
examination is performed at the follow-up visit, the sole
purpose is to determine whether the gestational sac is
present. After surgical or spontaneous expulsion, the uterus
will normally contain sonographically hyperechoic tissue
that consists of blood, blood clots, and decidua. Rarely does
this finding in women who have undergone medical abortion
indicate a need for intervention. In the absence of excessive
bleeding, health care providers can monitor such patients
based on symptoms.Guidelines for intervention vary for women who have a
persistent gestational sac on ultrasonography without
evidence of embryonic cardiac activity or continuing
development. Patients with a persistent gestational sac 1
week after treatment can safely receive another dose of
misoprostol or continue with expectant management
[32,52]. Studies indicate that even with a retained sac 2
weeks after mifepristone, intervention is unnecessary and
that expulsion will typically occur in the ensuing weeks
[45]. Women who prefer not to wait longer may choose to
have a surgical evacuation at any time. Most commonly,
women who are awaiting delayed expulsion will no longer
feel pregnant or have medication-induced symptoms;
patients will be waiting for the onset of bleeding or
cramping similar to anticipating the start of menses [53].
Health care providers must differentiate these women from
those who have incomplete expulsion of the pregnancy
tissue with symptoms, such as prolonged and irregular
bleeding episodes.
Continuing pregnancies are typically reported in less than
1% of women who begin medical abortion at or before 63
days of gestation with evidence-based regimens [54].
Ongoing pregnancy may be treated with uterine aspiration
or a repeat dose of vaginal misoprostol. In an analysis of data
from two randomized trials with 14 cases of ongoing
pregnancy with gestational cardiac activity, treatment with a
repeat dose of misoprostol, 800 mcg administered vaginally,
resulted in expulsion of the products of conception in five
cases (36%); in an additional four cases (29%), gestational
cardiac activity was no longer present at the next follow-up
visit [52]. If gestational cardiac activity persists at follow-up
after a second dose of misoprostol, uterine aspiration should
be performed. Repeat doses of buccal misoprostol to treat
ongoing pregnancy have not been studied.
Women who undergo medical abortion may need to
access emergency surgical intervention, and it is medically
appropriate to provide referral to another health care
provider. However, state or local laws may have additional
requirements. In women who receive mifepristone and
vaginal misoprostol, emergency curettage within the first
24 h of treatment is rare, occurring in 0.2% of patients [55].
Clinicians who wish to provide medical abortion services
either should be trained in surgical abortion or should be able
to refer to a clinician trained in surgical abortion.7. Clinical considerations and recommendations
7.1. Who are candidates for medical abortion with
mifepristone and misoprostol?
Women are candidates for medical abortion with
mifepristone and misoprostol if they meet the gestational
age criteria for the regimen and have no contraindications to
the medical abortion process. Women with twin gestations
can be treated with the same regimens as those with singleton
gestations [56]. Medical contraindications are infrequent.
153Society of Family Planning / Contraception 89 (2014) 148–161Most studies exclude women with anemia who have Hb
levels of less than 9.5 g/dL or less than 10 g/dL; accordingly,
the safety of medical abortion in women with anemia is
unknown. Although the transfusion rates associated with
medical abortion are low (0.05%), they exceed those
reported for surgical abortion in early pregnancy (0.01%)
[54,57].
Other medical contraindications to abortion with mifep-
ristone regimens include confirmed or suspected ectopic
pregnancy, intrauterine device (IUD) in place, current long-
term systemic corticosteroid therapy, chronic adrenal
failure, known coagulopathy or anticoagulant therapy, and
intolerance or allergy to mifepristone. Most clinical trials
also have excluded women with severe liver, renal or
respiratory disease or uncontrolled hypertension or cardio-
vascular disease (angina, valvular disease, arrhythmia or
cardiac failure).
Misoprostol should not be used in women who have an
allergy or intolerance to misoprostol or other prostaglandins.
Asthma is not a contraindication because misoprostol is a
weak bronchodilator.
Women are not good candidates formedical abortion if they
are unable or unwilling to adhere to care instructions, desire
quick completion of the abortion process, are not available for
follow-up contact or evaluation or cannot understand the
instructions because of language or comprehension barriers.
7.2. Which pretreatment laboratory tests are needed?
Confirmation of pregnancy is necessary before attempting
abortion, regardless of method. Preoperative assessment of
Hb or hematocrit is indicated when anemia is suspected. Rh
testing is standard of care in the United States, and RhD
immunoglobulin should be administered if indicated. Other
laboratory evaluations are not indicated but may be required
by local and state legislation.
7.3. What is the upper gestational age limit for use of
medical abortion?
The upper gestational age limit at which a medical
abortion regimen is still an option varies based on the types,
dosages, and routes of administration of the medications.
Complete abortion rates with all regimens are highest for
women with earlier gestations and are clinically similar in
women with pregnancies up to 42 days of gestation. After 49
days of gestation, evidence-based regimens have advantages
over the FDA-approved regimen and are medically prefer-
able (Table 2). After 49 days of gestation, the efficacy of the
FDA-approved regimen decreases significantly, and the
likelihood of continuing pregnancy increases [27]. However,
regimens using vaginal, sublingual and buccal misoprostol
provide efficacy rates when used up to 63 days of gestation
that exceed the approximately 92% efficacy of the FDA-
approved regimen when used up to 49 days of gestation
[24,29]. Moreover, the continuing pregnancy rates with these
alternative methods of administering misoprostol remainlow, at approximately 1% or less for vaginal, buccal and
sublingual regimens up to 63 days of gestation [32,58–60].
The amount of published data on sublingual regimens is
relatively small compared with vaginal regimens.
The use of the mifepristone–misoprostol regimen has
been evaluated for medical abortion in women with
pregnancies beyond 9 weeks of gestation, most commonly
with regimens that involve the use of vaginal misoprostol
and in an in-patient setting [61,62]. In a published review of
more than 1000 women who were observed as inpatients
after misoprostol treatment, primarily by the vaginal route,
the efficacy rate exceeded 92% for women with pregnancies
through 13 weeks of gestation (with a rate of 97% at 9–10
weeks of gestation), steadily decreasing to 92% for those
with gestations at 12–13 weeks [63]. Continuing pregnancy
rates were less than 1% for women with gestations through
11 weeks. The published experience with sublingual
misoprostol in this gestational age range is relatively small
[61,63].
A more recent US multicenter trial evaluated 629 women
with pregnancies from 57 days of gestation to 70 days of
gestation who received mifepristone with buccal misoprostol
in an outpatient setting [64]. Success rates were 94% for
women with gestations from 57 days to 63 days and 93% for
those with gestations from 64 days to 70 days, and
acceptability was high and similar for both gestational age
groups. However, the continuing pregnancy rate was 3% for
both groups.
7.4. Should prophylactic antibiotics be used in
medical abortion?
Uterine infection with medical abortion is uncommon, and
limited data exist to support the prophylactic use of
antibiotics in medical abortion. In a systematic review of 65
studies of heterogeneous design (prospective, retrospective,
and randomized), the overall frequency of diagnosed or
treated infection after medical abortion in more than 46,000
patients was 0.9% [65]. In these studies, as in most surgical
abortion studies, the diagnostic criteria for infection were
variable, which possibly led to an overestimation of infection.
Although concern regarding serious, rare and deadly
infection with clostridial bacteria in women who undergo
medical abortion has been raised, it has since become evident
that no specific connection exists between clostridial
organisms and medical abortion. Investigations have found
these organisms also are associated with other obstetric and
gynecologic processes and procedures, including spontane-
ous abortion, term delivery, surgical abortion, and cervical
cone or laser treatment for cervical dysplasia [66,67]. In
addition, it is now recognized that clostridial species are a
more common cause of pelvic infection than previously
believed [67].
Large retrospective analyses of medical abortion safety
conducted by Planned Parenthood Federation of America,
Inc, since 2001 showed a decrease over time in the serious
Table 2
Comparison of common medical abortion regimens
Common Regimens Overall Success
Rate (%)
Advantages and Disadvantages Gestational Age
Mifepristone 600 mg orally, followed by misoprostol
400 mcg orally 48 h later (regimen approved by
the US Food and Drug Administration)
92a Must return to office or clinic for misoprostol
administration; can be used only up to 49 days
of gestation
Up to 49 days
Mifepristone 200 mg orally, followed by misoprostol
800 mcg vaginally, buccally, or sublingually
24–48 h later (alternative evidence-based regimens;
with vaginal administration, misoprostol may be
administered 6 h or less after mifepristone)
95–99b–g Compared with the regimen approved by the
Food and Drug Administration:
•More effective
•Less time to expulsion
•Fewer adverse effects
•Lower cost
•More convenient because allows home
administration of misoprostol
Up to 63 days
Methotrexate, 50 mg/m2 intramuscularly or 50 mg
vaginally plus misoprostol, 800 mcg vaginally
3–7 days later
92–96h–j Compared with mifepristone–misoprostol regimen:
•Takes longer for expulsion in 20–30% of women
•Readily available medications
•Low drug cost
Up to 49 days
Misoprostol only, 800 mcg vaginally or sublingually
administered every 3 h for three doses (with
vaginal administration, dosing interval may be as
long as 12 h)
84–85k •Significantly higher incidence of adverse effects
than other regimens
•Readily available medication
•Low drug cost
Up to 63 days
a Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med
1998;338:1241–7.
b Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
Contraception 1999;59:1–6.
c Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral vs. vaginal misoprostol at one day after mifepristone for early medical abortion.
Contraception 2001;64:81–5.
d el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J
Med 1995; 332:983–7.
e von Hertzen H, Honkanen H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol
regimens after mifepristone for early medical abortion. I: Efficacy. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. BJOG
2003;110:808–18.
f Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours vs. 24 hours after mifepristone for
abortion. MOD Study Trial Group. Obstet Gynecol 2004;103:851–9.
g von Hertzen H, Huong NT, Piaggio G, Bayalag M, Cabezas E, Fang AH, et al. Misoprostol dose and route after mifepristone for early medical abortion: a
randomised controlled noninferiority trial. WHO Research Group on Postovulatory Methods of Fertility Regulation. BJOG 2010;117:1186–96.
h Creinin MD, Vittinghoff E, Schaff E, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol
1997;90:611–6.
i Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when
used with methotrexate for abortion. Contraception 1999;59:11–6.
j Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet
Gynecol 2002; 99:813–9.
k von Hertzen H, Piaggio G, Huong NT, Arustamyan K, Cabezas E, Gomez M, et al. Efficacy of two intervals and two routes of administration of
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hospitalization, sepsis, or death) with a change from vaginal
to buccal misoprostol (from 0.093% to 0.020%) and a further
decrease (to 0.006%) when routine provision of a 1-week
treatment course of doxycycline was started on the day of
mifepristone administration [68]. Because the study used
continuous prior time periods as the comparator, the addition
of a treatment course of antibiotics cannot be separated from
the effect of the switch in the route of misoprostol
administration. In a subsequent report, the risk of serious
infection in Planned Parenthood clinics increased to 0.013%
in 2009 and 0.019% in 2010 [54], a rate equal to the rate
noted before routine doxycycline provision. These data
indicate that the overall risk of serious infection with medicalabortion is very low and that buccal administration of
misoprostol may result in a lower risk of serious infection
compared with vaginal administration. The benefit suggested
by the addition of doxycycline may truly have been a period
effect. In addition, adherence to a doxycycline regimen of
14 tablets over 1 week is likely poor such that routine
treatment is not beneficial. Accordingly, no strong data exist
to support the universal use of prophylactic antibiotics for
medical abortion.
Although serious infections occur rarely in patients after
medical abortion, health care providers need to be aware of
the signs and symptoms. Sustained fever, tachycardia, or
severe abdominal pain or general malaise with or without
fever that occur more than 24 h after misoprostol
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infection. Clostridial toxic shock often resembles a flu-like
illness, so health care providers should have a high level of
suspicion for infection when symptoms consistent with flu
are present. Women with such infections typically have
hemoconcentration and significant leukocytosis without
fever and can rapidly progress to refractory hypotension
and death.
7.5. Is ultrasonography useful in the medical management
of abortion before treatment?
Before medical abortion is performed, gestational age
should be confirmed by clinical evaluation or ultrasound
examination. A US study found that women’s reported last
menstrual period combined with clinical estimation of
gestational age was accurate and would have resulted in
medical abortion erroneously offered to only 1.6% of women
after 63 days of gestation [69]. Because efficacy of some
regimens decreases significantly with increasing gestational
age, the clinical relevance of erroneous gestational age
assignment will vary based on the regimen used.
A potential concern when providing early abortion
services is the possibility of an undiagnosed extrauterine
gestation. The ectopic pregnancy rate in the general
population is approximately 19–21 per 1000 pregnancies
and may be slightly higher (21–24 per 1000 pregnancies)
among patients who receive Medicaid [70–72]. However,
ectopic pregnancy rates in studies of women who seek
abortion are consistently lower. A study of surgical abortion
in U.S. women with pregnancies less than 6 weeks of
gestation found the ectopic pregnancy rate to be 5.9 per 1000
pregnancies [73]. Similarly, the largest study of medical
abortion patients published involved 16,369 women with
pregnancies of 49 days of gestation or less, 21 of whom were
excluded from the analysis because of an ectopic pregnancy,
yielding an ectopic pregnancy rate of 1.3 per 1000
pregnancies [74]. Although ectopic pregnancy in a popula-
tion of women who seek early abortion is rare, women with
significant medical risk factors or history (i.e., unilateral
pain and vaginal bleeding) should have a pretreatment
ultrasonography.
If ultrasonography is performed, abdominal ultrasonog-
raphy is sensitive for diagnosing the presence or absence of a
gestational sac in nonobese women [75]. Thus, most women
can be initially screened with transabdominal ultrasonogra-
phy, reserving transvaginal ultrasonography for situations in
which further clarification is required.
7.6. What methods can be used to confirm complete
medical abortion?
Follow-up evaluation after medical abortion is performed
to diagnose and treat complications, including ongoing
pregnancy. The introduction of medical abortion into
widespread clinical practice has required continued emphasis
on follow-up because failure rates for medical abortion arehigher than those for surgical techniques, and misoprostol is
potentially teratogenic. Initial reports showed that mifepris-
tone and misoprostol can be integrated into clinical practice
with low rates of patients lost to follow-up [76,77]. However,
further reports reported loss-to-follow-up rates as high as
45% in clinical settings [78].
When the clinician and the patient think that expulsion has
occurred based on symptomatology, they are correct 96–99%
of the time [79,80]. However, a systematic review found that
women’s self-assessment alone or combined with clinical
assessment had low sensitivity (33−85%) and low positive
predictive value (6−66%) to detect ongoing pregnancy [81].
Follow-up after receiving mifepristone and misoprostol for
medical abortion is important, although an in-clinic
evaluation is not always necessary.
The FDA-approved regimen includes an evaluation at 2
weeks after mifepristone administration to assess for history
of bleeding and evidence of uterine involution on pelvic
examination. However, other options that allow evaluation
sooner with a high degree of accuracy to detect ongoing
pregnancy include in-clinic transvaginal ultrasound exami-
nation 1 week after treatment [82]; serum human chorionic
gonadotropin (hCG) level measurement before and 1 week
after treatment [83]; and telephone follow-up at 1 week, with
subsequent urine pregnancy testing at 2 weeks or 4 weeks
after treatment [80,84]. Although urine pregnancy testing
alone with standard high- or low-sensitivity tests has not
been shown to be a viable alternative, newer semiquantita-
tive urine hCG tests have shown promise in accurately
identifying ongoing pregnancies after medical abortion
[85,86].
Transvaginal ultrasonography is commonly used for
follow-up examination after medical abortion, primarily
because it provides a definitive assessment of whether or
not the products of conception have been expelled. Incorrect
interpretation of ultrasound examination results may lead to
unnecessary intervention.When an ultrasound examination is
performed at follow-up, the sole purpose is to determine
whether the gestational sac is present. For patients who are
below the threshold for visualization of a gestational sac,
follow-up with serum hCG testing is needed. The measure-
ment of endometrial thickness or other findings cannot
predict the need for future surgical intervention [82]. In
research trials, when a transvaginal ultrasound examination
shows no evidence of a gestational sac 1 week after
mifepristone use, only 1.6% ofwomenwill need a subsequent
surgical evacuation.
Serum hCG testing is another option for follow-up
examination after medical abortion, and it does not require
that the patient return to the same facility; she can obtain the
test at a location near her home or work. However, a phone
call to the patient to discuss the result is still necessary, so the
potential for failed follow-up exists in two ways: 1) the
patient must present to get a test, and 2) the patient must be
reached by phone. A serum hCG level decrease of at least
80% over 6–7 days after initiating treatment with
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[83]. In a trial that randomized women to follow-up in the
form of in-clinic transvaginal ultrasound examination or
serum hCG testing, 24.5% of patients were lost to follow-up,
with no significant differences reported in unplanned visits
and interventions by 2 weeks (6.6% vs. 8.2%, respectively)
or in dilation and curettage rates by 4 weeks (4.4% and 1.4%,
respectively) [87].
Another study examined follow-up rates for women that
chose ultrasound examination or hCG testing [88]. The loss-
to-follow-up rate was somewhat higher among women who
chose hCG testing (33.7% vs. 22.9%), but in multivariable
analysis, follow-up method was not associated with loss to
follow-up. Instead, loss to follow-up was found to be based
on patient factors, such as living at least 10 miles from the
clinic, prior pregnancy, unemployment, and a history of
induced abortion.
When patients are required to go to a facility for
assessment of medical abortion outcome, approximately
25% are lost to follow-up, which indicates the need for
development of other follow-up methods. Telephone follow-
up with subsequent urine pregnancy testing avoids the need
for the woman to go to a facility for her initial assessment. A
feasibility study of 139 US women had a 100% initial
follow-up rate and an overall follow-up of 97% when need
for in-person assessment, as determined by telephone
contact, was included; a key part of this trial was that the
ability to successfully contact the patient by phone was
assessed before medication distribution [80]. Another
promising method in development is an at-home semiquan-
titative urine hCG test; in a feasibility study of 394 women
who used the product, 1-week posttreatment sensitivity and
specificity were 100% and 97%, respectively [89]. The study
required the participants to return to the clinic on the day they
performed the at-home test to review the results, and 20%
were lost to follow-up. Thus, combining the semiquantitative
urine hCG test with telephone follow-up may hold the
most promise.
7.7. Do women have a preference for route of misoprostol
administration?
Many health care providers may offer women only one
option for misoprostol administration, even though all routes
are not the same. Vaginal routes of administration enable the
patients to complete the medical abortion process sooner
because of the ability to use the misoprostol 6 h or less from
the time of mifepristone administration [5,31]. Early studies
with mifepristone regimens demonstrated that women
preferred a shorter interval between medications [90].
Other research indicates women prefer oral routes of
administration to vaginal administration [11,91].
A US study with 139 participants allowed the women to
choose between buccal and vaginal misoprostol administra-
tion [80]. The women were fully informed of the efficacy
rates, the timing interval allowed for the two routes, andadverse effect rates based on available literature. Almost all
women (94%) chose vaginal misoprostol and 74% of these
women used the misoprostol at 6 h or less after the
mifepristone, which indicates that timing was a significant
factor in their choice.
7.8. How should a patient be counseled about potential
teratogenicity if a medical method fails to lead to abortion?
Because teratogenicity of medical abortifacients be-
comes an important issue if the pregnancy continues,
patients must be counseled before medical abortion
treatment of the need for a surgical abortion in the event
of a continuing pregnancy. No evidence exists to date of a
teratogenic effect of mifepristone. Evidence suggests that
misoprostol can result in congenital anomalies when used
during the first trimester, possibly because of mild uterine
contractions that lead to decreased blood flow during
organogenesis [92]. Anomalies associated with misoprostol
use that have been described in the literature include
defects in the frontal or temporal bones and, most
commonly, limb abnormalities with or without Möbius
syndrome (mask-like facies with bilateral sixth and seventh
nerve palsy and frequently coincident micrognathia) [93–
97]. A case–control study from Brazil compared 96 infants
with Möbius syndrome matched with 96 infants with
neural tube defects [96]. Exposure to misoprostol during
the first trimester was 49% and 3%, respectively [odds ratio
(OR), 29.7; 95% confidence interval (CI), 11.6–76]. Six
cases of limb reduction abnormalities in fetuses examined
after failed abortion with methotrexate and misoprostol also
have been reported [97]. Methotrexate exposure also is
characterized by a variety of malformations, including
growth restriction, limb defects, and craniofacial anomalies,
among others [98]. Because misoprostol is the common
agent used with every medical abortion regimen, health
care providers must counsel all women regarding potential
teratogenic effects.
7.9. Does medical abortion affect future fertility or
pregnancy outcomes?
Future fertility with medical abortion has been evaluated
within only a 1-year period after medical abortion in a group
of 93 women who received methotrexate and misoprostol for
abortion [99]. Although none of the women were actively
attempting to achieve pregnancy, 25% became pregnant, a
rate higher than the calculated rate expected for this group of
women using contraception. By comparison, another report
indicated a pregnancy rate of 13% within 1 year after a first
surgical abortion [100].
A comparative study from China enrolled more than
14,000 nulliparous women to compare outcomes of preg-
nancies after medical or surgical abortion and pregnancies in
women with no history of abortion [101]. Women who had a
prior mifepristone abortion were less likely to have preterm
birth compared with those women who had never been
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frequencies of low birth weight infants and mean lengths of
pregnancy were similar in both groups. No significant
differences were reported in risk of preterm delivery,
frequency of low birth weight infants, or mean infant birth
weight in the comparisons of women with previous
mifepristone abortion and women with surgical abortion. In
a registry-based study from Scotland, no association was
found between prior abortion and subsequent preterm birth
during the period 2000−2008, when 68% of abortions were
medical [102].
7.10. Who is qualified to perform medical abortion?
In addition to physicians, advanced practice clinicians,
such as nurse–midwives, physician assistants, and nurse
practitioners, possess the clinical and counseling skills
necessary to provide first-trimester medical abortion [103].
In a randomized controlled trial in Nepal, women random-
ized to receive medical abortion under the care of a staff
nurse had a statistically equivalent risk of complete abortion
compared with those under the care of a physician, and no
serious adverse events were reported [104]. This evidence
indicates that medical abortion also can be provided safely
and effectively by nonphysician clinicians, and in some
states, advance practice clinicians are allowed to provide
medical abortion. However, many states require that a
physician perform an abortion and prohibit provision of
medical abortion by nonphysician clinicians.
Telemedicine, which involves the use of video and
information technology to provide a medical service at a
distance, has been used to extend the reach of physicians
to provide medical abortion. In one model, patients seen at
a clinic without an on-site physician have a video
consultation with a physician located elsewhere. The
physician is able to review electronically the patient’s
medical history, and ultrasonography, if requested, can be
performed by a trained technician at the remote clinic. If
the patient is eligible for medical abortion, the physician
remotely opens a telepharmacy drawer containing the
mifepristone and misoprostol and instructs the patient how
to use it. This model was evaluated in a nonrandomized
study and found to be equally effective when compared
with an in-person visit with a physician; adverse events,
including ongoing pregnancy, occurred in 1.3% of patients
and were not statistically different between the two groups
[105]. Women who chose telemedicine medical abortion
were significantly more likely to say they would
recommend the service to a friend compared with
women who had an in-person visit with a physician (OR
1.72; 95% CI, 1.26–2.34) [105]. In an analysis of this
clinic system’s service-delivery statistics, after telemedi-
cine was introduced, a significant reduction in second-
trimester abortion was reported, and women in remote
parts of the state were more likely to obtain an abortion
than before [106]. Medical abortion can be provided safelyand effectively via telemedicine with a high level of patient
satisfaction; moreover, the model appears to improve access
to early abortion in areas that lack a physician health care
provider. Despite the medical evidence, several states have
passed legislation that bans the use of telemedicine to
provide abortion.
7.11. What is the recommended timing of contraception
provision after medical abortion?
Almost all contraceptive methods can be provided
immediately after uncomplicated first-trimester medical
abortion, and all are considered Category 1 for provision
after first-trimester abortion according to the U.S. Medical
Eligibility Criteria (meaning there is no restriction for use)
[107]. Oral contraceptives, patch, ring, depot medroxypro-
gesterone acetate, and subdermal implants all may be started
on the day of misoprostol administration [108,109].
However, this requires an additional visit to the clinic to
start depot medroxyprogesterone acetate and implants, and
research is exploring whether these methods can be
administered on the day of mifepristone without reducing
the efficacy of medical abortion.
The optimal timing of IUD insertion has been evaluated in
two randomized studies. One study randomized women to
insertion of a copper IUD 1 week after mifepristone vs. 4−6
weeks later [110]. Significantly more women in the early-
insertion group received an IUD (97% vs. 76%, pb.001).
Another study randomized women to insertion of either a
copper or levonorgestrel-containing IUD 5−9 days after
mifepristone vs. 3−4 weeks later [111]. Fewer women in the
delayed group attended the follow-up visit to insert the IUD
(1.5% vs. 11%, p=.03). In both studies, no significant
difference was found in expulsion rates by group; however,
the delayed-insertion groups had expulsion rates of 7−11%,
which is higher than the expulsion rate noted with immediate
IUD insertion after surgical abortion [112]. The risk of
expulsion of an IUD needs to be weighed against the risk that
the patient will not return for a delayed insertion.
Sterilization may be performed once abortion is confirmed.
8. Summary of recommendations and conclusions
The following recommendations are based primarily on
good and consistent scientific evidence (Level A):
Based on efficacy and adverse effect profile, evidence-
based protocols for medical abortion are superior to the
FDA-approved regimen. Vaginal, buccal, and sublingual
routes of misoprostol administration increase efficacy,
decrease continuing pregnancy rates, and increase the
gestational age range for use as compared with the FDA-
approved regimen.
Regimens that use low doses of mifepristone (200 mg)
have similar efficacy and lower costs compared with to
those that use mifepristone at 600 mg.
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prostol at home as part of a medical abortion regimen.
Medical abortion also can be provided safely and
effectively by nonphysician clinicians.
Follow-up after receiving mifepristone and misoprostol for
medical abortion is important, although an in-clinic
evaluation is not always necessary.
Misoprostol-only medical abortion regimens are signifi-
cantly less effective than those that use a combination of
mifepristone and misoprostol.
The following recommendations are based primarily on
limited scientific evidence (Level B):
Because teratogenicity of medical abortifacients becomes an
important issue if the pregnancy continues, patients must be
counseled beforemedical abortion treatment of the need for a
surgical abortion in the event of a continuing pregnancy.
Before medical abortion is performed, gestational age
should be confirmed by clinical evaluation or ultrasound
examination.
Nonsteroidal antiinflammatory drugs, such as ibuprofen, are
not contraindicated in women who undergo a medical
abortion and are appropriate first-line agents for pain
management.
Buccal administration of misoprostol may result in a lower
risk of serious infection compared with vaginal administra-
tion.
Medical abortion can be provided safely and effectively via
telemedicine with a high level of patient satisfaction;
moreover, the model appears to improve access to early
abortion in areas that lack a physician health care provider.
The following recommendations are based primarily on
consensus and expert opinion (Level C):
Women who undergo medical abortion may need to access
emergency surgical intervention, and it is medically
appropriate to provide referral to another health care
provider. However, state or local laws may have additional
requirements.
Clinicians who wish to provide medical abortion services
either should be trained in surgical abortion or should be
able to refer to a clinician trained in surgical abortion.
No strong data exist to support the universal use of
prophylactic antibiotics for medical abortion.
Rh testing is standard of care in the United States, and RhD
immunoglobulin should be administered if indicated.9. Proposed performance measure
Percentage of patients presenting for abortion before 63
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